TG Therapeutics announced positive Phase 1 results for its subcutaneous Briumvi, demonstrating good bioavailability, safety, and tolerability. This outcome reduces risks for the company's key clinical development program, with Phase 3 topline data expected by late 2026 or early 2027. The company also raised its 2026 U.S. sales guidance for intravenous Briumvi to $885–900 million, reflecting improved growth prospects. Key risks include potential Phase 3 underperformance and competition from other treatments in multiple sclerosis.
TG Therapeutics announced positive Phase 1 trial results for a new high-concentration subcutaneous formulation of BRIUMVI (ublituximab), showing good safety, tolerability, and effective drug exposure compared to the intravenous form. This subcutaneou...
TG Therapeutics published post-hoc data from Phase 3 ULTIMATE I & II trials showing BRIUMVI (ublituximab) significantly reduces annualized relapse rate by 56.7% compared to teriflunomide in treatment-naïve relapsing multiple sclerosis (RMS) patients....
